The Social Responsibility of Physicians as Agents of Public Health Services

The physician who is entrusted with a large quantity of resources for the treatment of ARF/MOSF has a social responsibility for optimizing the treatment, auditing the outcome, and where possible, preventing the illness. Best treatment includes not only modern techniques but also efficient organization and leadership of the ICU team. Audit is an individual responsibility, may be fruitfully pursued on a multicenter basis, and is a cost-containment discipline. Audit of the St. Thomas' Hospital ARF program has resulted in a predictive scoring formula. This is used to illustrate a cost-effective analysis related to disease severity. Prevention of ARF/MOSF is a challenge to emergency services. There may also be a considerable opportunity to prevent ARF in high-risk surgical patients. A randomized study carried out at St. George's Hospital illustrates the health gains which could result.     

HPLC法测定帕尼培南/倍他米隆的含量

建立了HPLC法测定帕尼培南 /倍他米隆的含量。色谱条件 :采用C18柱 (5 μm ,2 0 0mm×4 6mm) ,0 0 2mol/L磷酸盐缓冲液 (pH8 0 )—乙腈 (97∶3 )为流动相 ,柱温 45℃ ,检测波长 2 60nm。帕尼培南和倍他米隆分别在 119～ 478和 12 6～ 5 0 5 μg/ml范围内呈良好的线性关系 ,日内RSD分别为 0 4%和 0 5 % ,回收率分别为 99 8%和 10 0 0 % ,含量测定结果与进口药品注册标准方法所得结果相符。     

帕尼培南/倍他米隆治疗重症获得性肺炎疗效分析

目的 探讨帕尼培南/倍他米隆治疗重症医院获得性肺炎的效果.方法 采用回顾性调查方法,对1例应用帕尼培南/倍他米隆治疗的合并肝硬化的老年重症医院获得性肺炎患者进行分析,记录其治疗后的临床症状变化.结果 对于老年重症医院获得性肺炎患者,经验性使用帕尼培南/倍他米隆治疗能够有效抑制病原菌,并且不良反应少,治疗效果明显.结论 在治疗老年重症医院获得性肺炎患者过程中,早期、正确使用广谱抗生素,能够提高治愈率. Abstract： Objective To study the clinical effect of panipenem/betamipron on severe hospital acquired pneumonia (SHAP). Methods The clinical file of the SHAP patient with hepatocirrhosis, whose temperature and white blood cell counts were obtained as the index of treatment. Results It was proved that panipenem/betamipron was efficacious for severe hospital acquired pneumonia in patient with age over 65 years old and well tolerated with few adverse events for initial empirical therapy. Conclusions Panipenem/betamipron demonstrated good clinical and bacteriological efficacy in elderly patients with SHAP.     

帕尼培南-倍他米隆对重症下呼吸道感染的临床评价

目的　评价帕尼培南 倍他米隆治疗危重病人下呼吸道感染的临床疗效。方法　 14 0例下呼吸道感染的危重病人 ,随机分为治疗组 70例 ,对照组 70例。分别应用帕尼培南 倍他米隆和亚胺培南 西司他丁 ,剂量均为 2 0 g/d ,静脉滴注给药 ,疗程 7～ 14d。 结果　帕尼培南 倍他米隆和亚胺培南 西司他丁的临床有效率分别为 81 4%和 82 9% ,细菌清除率分别为 75%和 76 1%。均无明显不良反应。结论　帕尼培南 倍他米隆可作为重症下呼吸道感染有效和安全的抗生素     

注射用帕尼培南/倍他米隆的人体药动学研究

目的:考察注射用帕尼培南/倍他米隆在呼吸系统感染患者体内的药动学。方法:15名受试者静脉滴注注射用帕尼培南/倍他米隆(0.5g/0.5g)后,采用高效液相色谱(HPLC)法测定帕尼培南、倍他米隆的血药浓度,计算药动学参数。结果:帕尼培南、倍他米隆的平均药动学参数分别为t1/2α(0.30±0.20)、(0.10±0.05)h,t1/2β(1.4±0.3)、(0.61±0.20)h,AUC0～6.5h(42±8)、(20±5)mg·h·L-1,CLs(10.8±1.5)、(29.7±8.5)L·h-1,Vd(10.2±0.9)、(8.8±1.5)L。结论:帕尼培南/倍他米隆在呼吸系统感染患者体内的药动学及药效学评价可以指导临床应用。     

帕尼培南-倍他米隆治疗重症下呼吸道感染的临床疗效及药敏试验研究

目的　评价帕尼培南 -倍他米隆对于重症下呼吸道感染的临床疗效及对痰分离菌的体外抗菌活性。方法　将 75例重症下呼吸道细菌性感染患者随机分为试验组和对照组 ,观察帕尼培南 -倍他米隆的临床疗效 ;对痰分离菌进行帕尼培南 -倍他米隆和亚胺培南 -西司他丁药敏试验。结果　试验组和对照组的临床痊愈率分别为 6 5 8%和6 2 2 % ,细菌清除率分别为 82 1%和 84 6 % ,两组间差别均无显著性意义 (P >0 0 5 )。结论　帕尼培南 -倍他米隆治疗重症下呼吸道感染疗效可靠并具有良好的体外抗菌活性